Rare exceptions have been the application of chemotherapeutic-resistant metastatic melanoma M21 (covalent daunorubicin immunochemotherapeutics synthesized using anti-chondroitin sulfate proteoglycan 9.2.27 surface marker);[89;92;170] chemotherapeutic-resistant mammary carcinoma MCF-7AdrR (covalent anthracycline-ligand chemotherapeutics utilizing epidermal growth factor (EGF) or an EDF fragment);[171] and chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) populations (epirubicin-anti-HER2/neu,[66,85,102] epirubicin-anti-EGFR,[66] gemcitabine-HER2/neu[97,98]) respectively. This evidence concerns the gene ERBB2 and breast adenocarcinoma.